Q5135 Inj, tyenne, 1 mgInjection, tocilizumab-aazg (tyenne), biosimilar, 1 mg
Q5135 payment limit: $4.37 per 1 MG, effective October 1, 2026 through December 31, 2026, based on 2Q26 ASP data. Coinsurance 20%. Note: 8% of reference add-on applied.
65219-0584-01 Tyenne, FreseniUS Kabi USA, LLC: 162 billing units per package (1 SYRINGE, GLASS in 1 CARTON / .9 mL in 1 SYRINGE, GLASS)65219-0586-04 Tyenne, FreseniUS Kabi USA, LLC: 162 billing units per package (1 SYRINGE, GLASS in 1 CARTON / .9 mL in 1 SYRINGE, GLASS)65219-0590-04 Tyenne, FreseniUS Kabi USA, LLC: 80 billing units per package (1 VIAL, SINGLE-DOSE in 1 CARTON / 4 mL in 1 VIAL, SINGLE-DOSE)65219-0592-10 Tyenne, FreseniUS Kabi USA, LLC: 200 billing units per package (1 VIAL, SINGLE-DOSE in 1 CARTON / 10 mL in 1 VIAL, SINGLE-DOSE)65219-0594-20 Tyenne, FreseniUS Kabi USA, LLC: 400 billing units per package (1 VIAL, SINGLE-DOSE in 1 CARTON / 20 mL in 1 VIAL, SINGLE-DOSE)Status E: excluded from the PFS by regulation.
78 of 78 payer prior-auth lists that name Q5135 require prior authorization or set conditions: Aetna, Arkansas Blue Cross and Blue Shield, Blue Cross Blue Shield of Arizona (AZ Blue), Blue Cross and Blue Shield of Texas, Blue Shield of California Promise Health Plan, Cigna, HealthSpring, Humana, Molina Complete Care (Virginia), Molina Healthcare of California, Molina Healthcare of Idaho, Molina Healthcare of Illinois, Molina Healthcare of Michigan, Molina Healthcare of Mississippi, Molina Healthcare of New Mexico, Molina Healthcare of Utah, Neighborhood Health Partnership, Oxford Health Plans, Passport by Molina Healthcare (Kentucky), Rocky Mountain Health Plans, and others.
Q5135 appears in 43 coverage policies from Aetna, Blue Cross & Blue Shield of Mississippi, Centene, Health Care Service Corporation (BCBS IL, TX, OK, NM, MT), Premera Blue Cross, UnitedHealthcare, Wellmark Blue Cross Blue Shield.
| Payer | Policy | Role in policy | Reviewed | Document |
|---|---|---|---|---|
| Aetna | Abatacept (Orencia) (0720) Rinvoq, Xeljanz, Otezla, Ruxolitinib, Hydroxychloroquine, Sulfasalazine | listed, no stance | Jul 1, 2026 | payer document |
| Aetna | Canakinumab (Ilaris) (0881) | listed, no stance | Aug 3, 2026 | payer document |
| Aetna | Golimumab (Simponi and Simponi Aria) (0790) | listed, no stance | Jul 31, 2026 | payer document |
| Aetna | Graves' Ophthalmopathy Treatments (0419) Celecoxib, Gypenosides, Pioglitazone | not covered | Apr 23, 2026 | payer document |
| Aetna | Guselkumab (Tremfya) (1011) | listed, no stance | Jun 29, 2026 | payer document |
| Aetna | Rilonacept (Arcalyst) (0770) | listed, no stance | Sep 11, 2026 | payer document |
| Aetna | Secukinumab (Cosentyx) (0905) | listed, no stance | Aug 11, 2026 | payer document |
| Aetna | Siltuximab (Sylvant) (0884) | listed, no stance | Jun 3, 2026 | payer document |
| Aetna | Spesolimab-sbzo (Spevigo) (1013) | listed, no stance | Apr 2, 2026 | payer document |
| Aetna | Tildrakizumab-asmn (Ilumya) (1012) | listed, no stance | Jul 1, 2026 | payer document |
| Aetna | Tocilizumab (0799) | covered if criteria are met | Jun 30, 2026 | payer document |
| Aetna | Vedolizumab (Entyvio) (0885) | listed, no stance | Jun 30, 2026 | payer document |
| Blue Cross & Blue Shield of Mississippi | Antirheumatic Biologicals (S.5.01.404) | covered if criteria are met | payer document | |
| Blue Cross & Blue Shield of Mississippi | Antirheumatic Biologicals (L.5.01.404) | covered if criteria are met | payer document | |
| Blue Cross & Blue Shield of Mississippi | Biosimilar Medications (S.5.01.593) | listed, no stance | payer document | |
| Blue Cross & Blue Shield of Mississippi | Biosimilar Medications (L.5.01.593) | listed, no stance | payer document | |
| Blue Cross & Blue Shield of Mississippi | Giant Cell Arteritis (L.5.01.516) | listed, no stance | payer document | |
| Blue Cross & Blue Shield of Mississippi | Giant Cell Arteritis (S.5.01.516) | listed, no stance | payer document | |
| Blue Cross & Blue Shield of Mississippi | Interstitial Lung Disease (L.5.01.493) | covered if criteria are met | payer document | |
| Centene | Biologic and Non-biologic DMARDs (CP.CPA.194) | covered if criteria are met | May 1, 2026 | payer document |
| Centene | Biologic and Non-biologic DMARDs | covered if criteria are met | Aug 1, 2026 | payer document |
| Centene | Tocilizumab (Actemra), Tocilizumab-anoh (Avtozma), Tocilizumab-bavi (Tofidence), Tocilizumab-aazg (Tyenne) (CP.PHAR.263) | covered if criteria are met | May 1, 2026 | payer document |
| Health Care Service Corporation (BCBS IL, TX, OK, NM, MT) | Oncology and Supportive Care Medications (RX502.061) tqjs | Hybreza™ | listed, no stance | Jan 1, 2027 | payer document |
| Health Care Service Corporation (BCBS IL, TX, OK, NM, MT) | Specialty Medication Administration Site of Care HCPCS Codes J0129, J0174, J0175, J0180, J0218, J0219, J0221, J0222, J0223, J0224, | listed, no stance | Jan 1, 2026 | payer document |
| Health Care Service Corporation (BCBS IL, TX, OK, NM, MT) | Tocilizumab and Associated Biosimilar(s) (RX501.115) | listed, no stance | Jan 1, 2027 | payer document |
| Premera Blue Cross | (effective November 6, 2026) Site of Service: Drugs and Biologic Agents Page | 10 of 19 | ∞ | listed, no stance | Jul 14, 2026 | payer document |
| Premera Blue Cross | Medical Necessity Criteria for Custom Open Formulary (5.01.647) Page | 48 of 69 | ∞ | listed, no stance | Sep 8, 2026 | payer document |
| Premera Blue Cross | Pharmacologic Treatment of Interstitial Lung Disease (5.01.555) Page | 14 of 31 | ∞ | listed, no stance | May 25, 2026 | payer document |
| Premera Blue Cross | Pharmacotherapy of Arthropathies (5.01.550) | listed, no stance | Sep 8, 2026 | payer document |
| Premera Blue Cross | Pharmacotherapy of Miscellaneous Autoimmune Diseases (5.01.564) Page | 39 of 85 | ∞ | listed, no stance | Sep 8, 2026 | payer document |
| Premera Blue Cross | Site of Service: Drugs and Biologic Agents Page | 10 of 18 | ∞ | listed, no stance | Jul 14, 2026 | payer document |
| UnitedHealthcare | Maximum Dosage and Frequency (2026D0034AU) | listed, no stance | Aug 1, 2026 | payer document |
| UnitedHealthcare | Maximum Dosage and Frequency (CS2026D0034AV) | listed, no stance | Aug 1, 2026 | payer document |
| UnitedHealthcare | Maximum Dosage and Frequency (for Ohio Only) (CSOH2026D0034.K) | listed, no stance | May 1, 2026 | payer document |
| UnitedHealthcare | Maximum Dosage and Frequency (for Pennsylvania Only) (CSPA2026D0034AS) | listed, no stance | May 1, 2026 | payer document |
| UnitedHealthcare | Medicare Part B Step Therapy Programs (IAP.001.30) Preferred | listed, no stance | Jul 1, 2026 | payer document |
| UnitedHealthcare | Provider Administered Drugs – Site of Care (2026D0121W) | listed, no stance | Sep 1, 2026 | payer document |
| UnitedHealthcare | Provider Administered Drugs – Site of Care (CS2026D0121P) | listed, no stance | Jul 1, 2026 | payer document |
| UnitedHealthcare | Provider Administered Drugs – Site of Care (for Ohio Only) (CSOH2026D0121.I) | listed, no stance | Aug 1, 2026 | payer document |
| UnitedHealthcare | Provider Administered Drugs – Site of Care (for Pennsylvania Only) (CSPA2026D00121J) | listed, no stance | Aug 1, 2026 | payer document |
| UnitedHealthcare | Tocilizumab (CS2026D0043AL) | listed, no stance | Sep 1, 2026 | payer document |
| UnitedHealthcare | Tocilizumab Injection for Intravenous Infusion (2026D0043Z) | listed, no stance | Jul 1, 2026 | payer document |
| Wellmark Blue Cross Blue Shield | Tocilizumab (05.01.31) | listed, no stance | Jun 1, 2026 | payer document |
Prior authorization required or conditional in IN, VA, VT.
From payers' published prior-auth lists, coverage policies and state Medicaid fee schedules, updated Oct 16, 2026. The role is what the policy's own code table or text says about the code. Not a guarantee of coverage or payment; verify with the payer. CPT® is a registered trademark of the American Medical Association.